Breaking News

Financial Report: Wockhardt

October 25, 2013

Earnings drop 70% as three India plants face export restrictions

Wockhardt
 
2Q Revenues: 12.0 billion rupees (-11%)

2Q Earnings: 1.4 billion rupees (-70%)

YTD Revenues: 26.0 billion rupees (-5%)

YTD Earnings: 4.6 billion rupees (-44%)

Comments: Results were impacted by restrictions on shipping medicines to the U.S. and UK from one of its factories after health regulators identified deficiencies at the plant. The UK’s MHRA recently added restrictions on exports from two other factories. According to a Wockhardt statement, the U.S. import alert, reported in May, could cost about $100 million in annual sales. It has subsequently taken measures to improve quality oversight at its factories, including the appointment of a new quality chief and hiring of outside consultants.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks